Pacritinib
- Generic Name
- Pacritinib
- Brand Names
- Vonjo
- Drug Type
- Small Molecule
- Chemical Formula
- C28H32N4O3
- CAS Number
- 937272-79-2
- Unique Ingredient Identifier
- G22N65IL3O
- Background
Myelofibrosis (MF) is a rare disorder characterized by hematopoietic abnormalities and fibrosis within the bone marrow. The underlying cause of primary MF is unknown, but secondary MF can arise in patients with a history of polycythemia vera or essential thrombocythemia. While some patients may remain asymptomatic, typical symptoms of MF arise from abnormali...
- Indication
Pacritinib is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 x 10/L.
...
- Associated Conditions
- High-Risk Secondary Myelofibrosis, High risk Primary Myelofibrosis (PMF), Intermediate risk Primary Myelofibrosis (PMF), Intermediate risk Secondary Myelofibrosis
- Associated Therapies
- -
PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2018-10-22
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 40
- Registration Number
- NCT02807077
- Locations
- π²π©
Republican Clinical Hospital, Chisinau, Moldova, Republic of
π·π΄Carol Davila Nephrology Hospital Bucharest, Bucharest, Romania
π©πͺAPEX GmbH, Munich, Germany
Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 18
- Registration Number
- NCT02807116
- Locations
- πΊπΈ
Covance Clinical Research Unit, Daytona Beach, Florida, United States
To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 20
- Registration Number
- NCT02807051
- Locations
- πΊπΈ
Covance Clinical Research Unit, Daytona Beach, Florida, United States
Investigate Absorption, Metabolism, Excretion, and Mass Balance of Pacritinib
- First Posted Date
- 2016-06-17
- Last Posted Date
- 2016-06-17
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 6
- Registration Number
- NCT02803762
- Locations
- π³π±
QPS Netherlands B.V., Groningen, Netherlands
Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects
- First Posted Date
- 2016-05-09
- Last Posted Date
- 2020-03-06
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 28
- Registration Number
- NCT02765724
- Locations
- π©πͺ
APEX GmbH, Munich, Germany
π²π©Republican Clinical Hospital, Chisinau, Moldova, Republic of
Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- Conditions
- Interventions
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2017-09-06
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Registration Number
- NCT02677948
- Locations
- πΊπΈ
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
πΊπΈMayo Clinic, Rochester, Minnesota, United States
Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2017-05-08
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT02564536
Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML
- Conditions
- Interventions
- First Posted Date
- 2015-08-25
- Last Posted Date
- 2018-06-15
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 13
- Registration Number
- NCT02532010
- Locations
- πΊπΈ
Weill Cornell Medical College, New York, New York, United States
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
- First Posted Date
- 2015-06-11
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT02469415
- Locations
- πΊπΈ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)
- First Posted Date
- 2015-04-07
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT02410551
- Locations
- πΊπΈ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.